Re-188 P 2045

N/A

Report date: 2025/11/20 13:28:19
NME

Base Information

Drug NameRe-188 P 2045
Drug Alias NameNeoTideTozarideP2045BAY-865284Rhenium-188-P-2045 +[9] 
ClassificationRadiation-emitting products > Nuclides > Rhenium > 188ReRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Radioactive therapeutic agent +[4] 
Mechanisms of ActionIonising radiation emittersSomatostatin receptor 2 modulators
TargetsSomatostatin receptor 2
Therapy Area/IndicationsNeoplasm Recurrence, LocalSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesAndarix Pharmaceuticals Inc
Inactive CompaniesUniversity Of Maryland, Baltimore
Active IndicationsNeoplasm Recurrence, LocalCarcinoma, Non-Small-Cell LungLung Neoplasms +[4] 
Inactive IndicationsSmall Cell Lung CarcinomaNeuroendocrine Tumors

Other Information

ATC CodeN/A
Related LinksN/A